D-0961-2022 Class II Terminated
FDA drug recall D-0961-2022 was initiated by Nephron Sterile Compounding Center LLC on May 18, 2022 and is designated Class II. Reason for recall: Lack of Assurance of Sterility The recall status is terminated (terminated Aug 23, 2024). Affected quantity: 115640 syringes.
Recall Details
- Product Type
- Drugs
- Report Date
- Jun 8, 2022
- Initiation Date
- May 18, 2022
- Termination Date
- Aug 23, 2024
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 115640 syringes
Product Description
Labetalol HCl Injection, USP, 20 mg/4 mL (5 mg/mL), Preservative Free, 4 mL Pre-Filled Syringe, 5 x 4 mL Pre-Filled Syringes, 6 x 5 Syringe Carton, Rx Only, Nephron 503B outsourcing facility, 4500 12th St. Extension, West Columbia, SC 29172, NDC: 69374-946-04
Reason for Recall
Lack of Assurance of Sterility
Distribution Pattern
Nationwide in the USA
Code Information
Lots: LB1020A, LB1022A Exp. 5/21/2022; LB2003A, Exp. 8/5/2022; LB2007A, Exp. 9/20/2022
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0961-2022
- openFDA file date
- Oct 23, 2026
- Loaded by RegDataLab
- Oct 26, 2026